Frits Stulp

Frits Stulp is Managing Director of Iperion - a Deloitte business, where he leads a team of regulatory/IDMP experts active in various projects to deliver value to both pharmaceutical companies as well as regulators. In addition to having more than two decades’ industry and consultancy experience, Frits is regarded internationally as a subject matter expert on IDMP and he proactively shares his rich knowledge and experience wherever he can. Iperion, now part of Deloitte, is a globally-operating life sciences consultancy firm which is paving the way to digital healthcare, by supporting standardization and ensuring the right technology, systems and processes are in place to enable insightful business decision-making and innovation.

Email frits.stulp@iperion.com

www.iperion.com

Articles

Why Pharma’s Approach to IDMP Today Will Matter to Patients & Physicians Tomorrow

The Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.

IDMP: Making Patients the Priority in 2020

2019 saw progress towards ISO Identification of Medicinal Products data standards implementation, but making patients front and central to project focus must remain a priority, says Frits Stulp.

Product Data: Not Just for Regulators

It is worth keeping patients, clinicians, pharmacists and the wider public front of mind when evaluating priorities and best next steps towards Identification of Medicinal Products(IMDP) and other emerging standards, writes Frits Stulp.